RxDoctor Payments Data

Christopher Avendano, MD

Pulmonary Disease · Sandusky, OHNPI 1003868126

Payments from drug & device makers

$976in general payments, 2019–2025

Across 55 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$232
  • Boehringer Ingelheim$141
  • Sanofi$115
  • AstraZeneca$99
  • United Therapeutics Corporation$63
  • Mylan Specialty L.p.$49
  • plus $279 from 11 others

What the payments were for

  • Food & beverage$90192%
  • Education$748%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$976 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$202,104
Medicare patients
735
Services billed
2,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter313$321,092
UptraviSelexipag12$279,273
Breo ElliptaFluticasone/Vilanterol120$78,167
Spiriva RespimatTiotropium Bromide73$63,184
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$33,585
Spiriva HandihalerTiotropium Bromide28$26,835
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$25,497
Tiotropium Bromide26$24,964
Advair HfaFluticasone Propion/Salmeterol55$20,964
XareltoRivaroxaban17$15,329
DuleraMometasone/Formoterol23$13,228
Incruse ElliptaUmeclidinium Bromide30$13,077
SymbicortBudesonide/Formoterol Fumarate34$13,016
Arnuity ElliptaFluticasone Furoate28$12,692
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate60$11,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$232$458,612534 claims
Actelion Pharmaceuticals US, Inc.Uptravi$48$279,27312 claims
Boehringer IngelheimSpiriva Respimat$141$63,18473 claims
AstraZenecaBreztri Aerosphere, Symbicort$99$38,51366 claims
Johnson & JohnsonXarelto$17$15,32917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Sandusky

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →